Trial Profile

A Phase 2 Proof-of-Concept Study to Evaluate the Effects of NDX-1017 to Treat Alzheimer's Disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 02 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fosgonimeton (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Athira Pharma

Most Recent Events

11 Apr 2019 According to a M3 Biotechnology media release, this study is planned to start in 2019.
11 Apr 2019 According to a M3 Biotechnology media release, the companys phase 2 trials including this trial will be supported in part by the Alzheimer's Association through its PART THE CLOUD to RESCUE Program.
11 Apr 2019 According to a M3 Biotechnology media release, the company has changed its name from M3 Biotechnology to Athira Pharma, Inc.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com